Seeing Machines Limited
30 August 2006
30 August 2006
SEEING MACHINES LIMITED
('Seeing Machines' or 'the Company')
GLAUCOMA PROJECT CLINICAL STUDY RESULTS
Seeing Machines Limited (AIM: SEE), a leading developer of advanced computer
based imaging software systems, recently concluded the initial phase of a second
clinical study (CT2) of the glaucoma testing device. The purpose of this
investigation was to build on the positive results of the CT1 clinical study
announced in January 2006 by further exploring the operational parameters of the
device's behaviour in a clinical setting.
Importantly, the outcome of this work has clearly illuminated a small number of
design parameters that need further investigation prior to the introduction of
the device. Accordingly an additional clinical study (T13) has been instituted
that will explore these issues allowing for a resumption of the second phase of
the major CT2 study. The T13 study will commence today.
The Company is continuing to progress the other commercialisation activities
required to bring the device to market including regulatory approval, hardware
design and software development. All of these activities are supported by the
recently awarded Commercial Ready Grant from the Australian Government which
will allow for the expedited completion of the work. The Company remains
committed to releasing the glaucoma diagnostic device during 2007.
Enquiries:
Seeing Machines Limited Insinger de Beaufort Parkgreen Communications
Nick Cerneaz, CEO Simon Fox Justine Howarth /
Victoria Thomas
+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713
www.seeingmachines.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.